Participant characteristics
| All participants (n=86), n (%) | European participants (n=58), n (%) | |
| Neoadjuvant therapy | ||
| No CRT | 2 (2) | 1 (2) |
| Chemotherapy | 17 (20) | 12 (21) |
| Chemoradiotherapy other CROSS | 8 (9) | 3 (5) |
| Chemoradiotherapy CROSS | 59 (69) | 42 (72) |
| Surgical approach | ||
| Abdominal and transhiatal approach | 3 (3) | 1 (2) |
| Abdominal and transthoracic approach | 81 (94) | 57 (98) |
| Other | 2 (2) | 0 (0) |
| Location of anastomoses | ||
| Intrathoracic anastomosis | 60 (70) | 52 (89) |
| Cervical anastomosis | 21 (24) | 6 (11) |
| Other | 5 (6) | 0 (0) |
| Surgical technique | ||
| Open surgery | 20 (23) | 11 (19) |
| Minimally invasive surgery | 54 (63) | 36 (62) |
| Hybrid surgery | 21 (24) | 14 (24) |
| Robot surgery | 5 (6) | 3 (5) |
Based on the routine approach for treatment of T2–3 resectable distal oesophageal cancer. This scheme includes intravenous carboplatin and intravenous paclitaxel with concurrent radiotherapy followed by surgery. According to CRT scheme used in the CROSS trial (ref).
CROSS, Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (ref); CRT, chemoradiotherapy.